ArticleEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2012
The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating.
Article in European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.CNS drugs · 2013Trial
- Untangling Mephedrone-Induced Social Reward in Rats-The Involvement of Oxytocin and Vasopressin VGenes, brain, and behavior · 2026Article
- Dual Oxytocin Signals in Striatal Astrocytes.Biomolecules · 2025Article
- Neurobehavioral and neurodevelopmental profiles of a heuristic genetic model of differential schizophrenia- and addiction-relevant features: The RHA vs. RLA rats.Neuroscience and biobehavioral reviews · 2021Review
- Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment.International journal of molecular sciences · 2021Review
- Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats.Neuropharmacology · 2019Article
- Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.Neuroscience and biobehavioral reviews · 2017Review
- Reversal of social deficits by subchronic oxytocin in two autism mouse models.Neuropharmacology · 2016Article
- Effects of oxytocin on background anxiety in rats with high or low baseline startle.Psychopharmacology · 2016Article
- Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation.Journal of neuroendocrinology · 2016Article
- A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia.Biological psychiatry · 2016Review
- Peripherally administered oxytocin modulates latent inhibition in a manner consistent with antipsychotic drugs.Behavioural brain research · 2015Article
- A Role for Oxytocin in the Etiology and Treatment of Schizophrenia.Frontiers in endocrinology · 2015Review
- Oxytocin and Vasopressin Receptor Gene Polymorphisms: Role in Social and Psychiatric Traits.Frontiers in neuroscience · 2015Review
- The Effect of Oxytocin on Social and Non-Social Behaviour and Striatal Protein Expression in C57BL/6N Mice.PloS one · 2015Article
- Chronic and acute intranasal oxytocin produce divergent social effects in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.Frontiers in neuroscience · 2013Article
- The effects of vasopressin and oxytocin on methamphetamine-induced place preference behaviour in rats.Metabolic brain disease · 2012Article
- Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.Acta neuropsychiatrica · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Converging evidence from preclinical and clinical studies suggest that oxytocin has therapeutic potential for schizophrenia and other neuropsychiatric disorders. Prepulse inhibition of the startle reflex (PPI) is a measure of sensorimotor gating, an important brain function involved in filtering environmental information. We previously demonstrated that systemically administered oxytocin reversed psychostimulant-induced PPI deficits in rats suggesting that oxytocin can produce antipsychotic-like central effects. That finding was supported by a recent trial in humans, which found that intranasal oxytocin reduced symptoms of schizophrenia. The goal of this study was to extend this line of investigation by testing the effects of oxytocin, and a structural analog of oxytocin, carbetocin, on non-pharmacological deficits in PPI. In experiment 1, Brown Norway (BN) rats, a rat strain that has naturally low PPI, were given either saline or one of three doses of oxytocin (0.04-1.0 mg/kg, sc). In experiment 2, BN rats were given either saline, one of three doses of carbetocin (0.04-1.0 mg/kg) or oxytocin (1 mg/kg). PPI and acoustic startle response (ASR) of rats were tested. Oxytocin significantly increased PPI (P<0.01) and decreased ASR levels (P<0.01) in BN rats in a dose-dependent fashion. In contrast, carbetocin had no effect on PPI levels or ASR. The facilitation of BN PPI by oxytocin is similar to what we have previously observed with clozapine and thus further supports oxytocin having antipsychotic properties. In contrast to oxytocin, our data do not support the use of carbetocin as an antipsychotic drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.